Symptomatic medications, l-Dopa and dopaminergic agents, remain the only clinically pertinent pharmacological treatment proven effective and available for the large population of patients with Parkinson's disease. The challenge for the pharmaceutical industry is to develop disease-modifying drugs which could arrest, delay or at least oppose the progression of the specific pathogenic processes underlying Parkinson's disease. The purpose of this review, based on recent biological and genetic data to be validated with appropriate animal models, was to re-examine the putative neuroprotective agents in Parkinson's disease and discuss the development of new strategies with the ultimate goal of demonstrating neurocytoprotective activity in this neurodegenerative disease. Since guidelines for research on neurocytoprotective drugs remain to be written, innovation will be the key to success of future clinical trials. It is reasonable to expect that future advances in our understanding of the pathogenic processes of Parkinson's disease will open the way to new perspectives for the treatment of other neurodegenerative diseases.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1016/j.pneurobio.2007.10.003 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Healthcare utilization and costs for patients with Parkinson's disease in Taiwan.
BMC Neurol
January 2025
Department of Public Health, College of Medicine, National Cheng Kung University, No.1, University Road, Tainan City, 701, Taiwan.
Background: Parkinson's disease (PD) exerts a considerable burden on the elderly. Studies on long-term costs for Parkinson's disease patients in Taiwan are not available.
Objectives: This study aims to examine the medical resource utilization and medical costs including drug costs for PD patients in Taiwan over up to 15 years of follow-up.
Exploring the stigma experienced by people affected by Parkinson's disease: a systematic review.
BMC Public Health
January 2025
School of Nursing and Midwifery, Queen's University Belfast, Belfast, Northern Ireland, UK.
Background: Stigma significantly impacts individuals with Parkinson's disease (PD) and their caregivers, exacerbating social isolation, psychological distress, and reducing quality of life (QoL). Although considerable research has been conducted on PD's clinical aspects, the social and emotional challenges, like stigma, remain underexplored. Addressing stigma is crucial for enhancing well-being, fostering inclusivity and improving access to care and support.
View Article and Find Full Text PDFSpace exploration and risk of Parkinson's disease: a perspective review.
NPJ Microgravity
January 2025
Department of Biological Science, Boise State University, Boise, ID, 83725, USA.
Systemic mitochondrial dysfunction, dopamine loss, sustained structural changes in the basal ganglia including reduced tyrosine hydroxylase, and altered gait- these effects observed in space-flown animals and astronauts mirrors Parkinson's disease (PD). Evidence of mitochondrial changes in space-flown human cells, examined through the lens of PD, suggests that spaceflight-induced PD-like molecular changes are important to monitor during deep space exploration. These changes, may potentially elevate the risk of PD in astronauts.
View Article and Find Full Text PDFEstablishing a robust triangulation framework to explore the relationship between hearing loss and Parkinson's disease.
NPJ Parkinsons Dis
January 2025
Department of Biostatistics, School of Public Health, Xuzhou Medical University, 221004, Xuzhou, Jiangsu, China.
The relationship between hearing loss (HL) and Parkinson's disease (PD) remains unclear. Using individual-level and summary-level data from the UK Biobank and the largest genome-wide association studies, we examined this link through observational, Mendelian randomization and genetic pleiotropy analyses. Among 158,229 participants, PD risk rose with HL severity especially in elder and males, and hearing aids significantly reduced PD risk in males.
View Article and Find Full Text PDFKey shifts in frontoparietal network activity in Parkinson's disease.
NPJ Parkinsons Dis
January 2025
Brain Electrophysiology and Epilepsy Lab (BEE-L), Epilepsy and EEG Unit, Neurological Institute, Tel Aviv Sourasky Medical Center, Tel Aviv, Israel.
We aimed to study the effect of Parkinson's disease (PD) and motor-cognitive load on the interplay between activation level and spatial complexity. To that end, 68 PD patients and 30 controls underwent electroencephalography (EEG) recording while executing visual single- and dual- Go/No-go tasks. The EEG underwent source localization, followed by parcellation of the neural activity into 116 regions of interest.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!